Skip to main content
. 2019 Sep 25;5(9):eaaw6499. doi: 10.1126/sciadv.aaw6499

Fig. 4. In vivo siRIPK4 delivered by HNTs inhibits tumor promotion of T24 bladder cancer cells in an in situ model of bladder cancer (n = 12 rats in each group).

Fig. 4

(A) Representative excised bladders and H&E-stained tissue slices (muscle-invasive bladder cancer: ≥stage pT2) treated with PBS. (B) Representative excised bladders and H&E-stained tissue slices (muscle-invasive bladder cancer: ≥stage pT2) treated with siRIPK4. (C) Representative excised bladders and H&E-stained tissue slices (muscle-invasive bladder cancer: ≥stage pT2) treated with HNTs. (D) Representative excised bladders and H&E-stained tissue slices (noninvasive papillary carcinoma: stage pTa) treated with HNTs/siRIPK4. (Photo credit: Jianye Liu and Ke Cao, The Third Xiangya Hospital of Central South University).